Shionogi Stock - Long-term strategy in a changing pharma market
20.06.2026 - 22:19:37 | ad-hoc-news.de
Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 20:17 UTC. Details in the imprint.
Shionogi (JP3347200002) is a mid-sized Japanese pharmaceutical group with a long history in anti-infectives and a growing focus on chronic and specialty indications. With no fresh market-moving headlines today, the spotlight shifts to its long-term strategy and earnings profile.
Background and price data on Shionogi stock
Key figures, strategy updates and historical disclosures help frame how Shionogi generates its earnings and where the stock might fit in the wider pharma landscape.
How Shionogi presents itself
Shionogi describes itself as a research-driven pharmaceutical company focused on infectious diseases, central nervous system disorders and other high-need areas. Its latest integrated report places strong emphasis on “protecting people’s health worldwide” and selective global expansion. Shionogi integrated report
The company highlights long-standing expertise in antibiotics and antiviral drugs, but also invests in vaccines and novel modalities such as biologics. Management repeatedly points to a capital-light partnering model outside Japan, using alliances rather than building heavy commercial infrastructure alone.
Long-term earnings and capital allocation
Shionogi’s most recent full-year results for the fiscal year ended 03/31/2025 showed revenue equivalent to several hundred billion JPY, with operating margin comfortably in the double digits, according to company disclosures. IR brief report
The group combines internal R&D with a relatively conservative balance sheet and continuous dividends. On balance, it positions shareholder returns as one pillar alongside reinvestment into pipeline assets and targeted in-licensing.
The product behind the stock
Shionogi’s core business is the development and commercialization of prescription medicines, notably in infectious diseases where it has marketed antibiotics and antiviral treatments, as well as newer vaccines and therapies for chronic conditions through its global network of partners and licensees.
Where the stock trades today
The shares of Shionogi (JP3347200002) trade on the Tokyo Stock Exchange at JPY 7,126.00 as of 06/18/2026, 15:00 JST.
Key facts on Shionogi stock
- Company: Shionogi & Co., Ltd.
- ISIN: JP3347200002
- WKN: 859549
- Ticker: 4507
- Venue: TSE
- Price (as of 06/18/2026, 15:00 JST): 7,126.00 JPY
- Market cap: 1,940,000,000,000 JPY (as of 06/18/2026)
- Sector / Industry: Pharmaceuticals & Biotechnology
- Index membership: TOPIX, other Tokyo benchmarks
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
